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Abstract
Biofilm formation is important for infection by many pathogens. Bordetella bronchiseptica
causes respiratory tract infections in mammals and forms biofilm structures in nasal epithe-
lium of infected mice. We previously demonstrated that cyclic di-GMP is involved in biofilm
formation in B. bronchiseptica. In the present work, based on their previously reported func-
tion in Pseudomonas fluorescens, we identified three genes in the B. bronchiseptica
genome likely involved in c-di-GMP-dependent biofilm formation: brtA, lapD and lapG.
Genetic analysis confirmed a role for BrtA, LapD and LapG in biofilm formation using micro-
titer plate assays, as well as scanning electron and fluorescent microscopy to analyze the
phenotypes of mutants lacking these proteins. In vitro and in vivo studies showed that the
protease LapG of B. bronchiseptica cleaves the N-terminal domain of BrtA, as well as the
LapA protein of P. fluorescens, indicating functional conservation between these species.
Furthermore, while BrtA and LapG appear to have little or no impact on colonization in a
mouse model of infection, a B. bronchiseptica strain lacking the LapG protease has a signif-
icantly higher rate of inducing a severe disease outcome compared to the wild type. These
findings support a role for c-di-GMP acting through BrtA/LapD/LapG to modulate biofilm for-
mation, as well as impact pathogenesis, by B. bronchiseptica
Introduction
Bordetella bronchiseptica is a Gram-negative bacterium that causes respiratory tract infections in
mammals, atrophic rhinitis in pigs, kennel cough in dogs and snuffles in rabbits [1]. B. bronchi-
septica has a variety of virulence factors that allow host infection. Each factor, such as pertactin,
filamentous hemagglutinin, adenylate cyclase, the type three secretory system and lipopolysac-
charide are likely to perform specific functions required for successful colonization [2–6].
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The ability of Bordetella spp. to form biofilms has been reported in previous work, including
the ability of B. bronchiseptica to form biofilms on abiotic surfaces regulated by the two-com-
ponent system BvgAS [7,8]. As has been found for other biofilm-forming organisms, extracel-
lular DNA (eDNA) and exopolysaccharide are important for biofilm formation by B.
bronchiseptica [9,10]. Particularly in Bordetella, BvgAS-regulated factors, including the fila-
mentous hemagglutinin and adenylate cyclase, may also participate in biofilm formation
[7,11]. Static growth in intermediate nicotinic acid concentrations, a regulator of the BvgAS
system, resulted in the best conditions for promoting biofilm formation [8]. Studies from our
group and others indicate that biofilm is enhanced in the intermediate phase [7,12], however,
there are conflicting findings regarding BvgAS-dependent biofilm regulation [8]. Furthermore,
transcriptome analysis has shown that more than 33% of the B. bronchiseptica genes are differ-
entially regulated during biofilm formation compared to planktonic culture [13]. Thus, further
studies are needed to elucidate all factors affecting biofilm formation.
Sloan and colleagues observed biofilm-like structures in vivo in the nasal epithelium of B.
bronchiseptica infected mice, and these communities expressed a polysaccharide essential for
in vivo biofilm development [9]. The absence of polysaccharides, key factor for in vitro biofilm
formation, also impaired infection suggesting that biofilm formation may also participate in
host-pathogen interactions [9]. Thus, biofilm formation may play an important role in host-B.
bronchiseptica interactions. Recently, we showed that bis-(30-50)-cyclic-dimeric guanosine
monophosphate (c-di-GMP) regulates motility and biofilm formation in B. bronchiseptica
[12]. C-di-GMP is a bacterial second messenger known to regulate a variety of cellular pro-
cesses including biofilm formation, motility and virulence of bacterial pathogens [14,15]. Like
in other bacteria where c-di-GMP-related functions have been studied, high c-di-GMP levels
in B. bronchiseptica correlated with an enhanced biofilm formation phenotype [12]. However,
in this previous study we did not uncover the mechanism by which c-di-GMP enhanced bio-
film formation in B. bronchiseptica.
Here we confirm the role for the Bvg-regulated adhesin BrtA, a putative homolog of the
well-characterized LapA adhesin of Pseudomonas fluorescens, in biofilm formation by B.
bronchiseptica, as has recently been reported by Nishikawa and colleagues [16]. Furthermore,
we show that the c-di-GMP receptor LapD and the LapD-regulated protease LapG also partici-
pate in biofilm formation by B. bronchiseptica, likely via the control of BrtA localization to the
cell surface as has been reported for the LapA adhesin of P. fluorescens. We also present data
that the appropriate control of BrtA via LapG appears to be important for modulating patho-
genesis in a mouse model of infection. Thus, this work describes the basis of c-di-GMP-medi-
ated control of biofilm formation in B. bronchiseptica, both in vivo and in vitro.
Materials and Methods
Ethics Statement
This study was performed in strict accordance with animal use protocols approved by Faculty
of Sciences, National University of La Plata, Institutional Animal Care and Use Committee
(IACUC), protocol number 007-00-15. All animals were properly anesthetized with isofluor-
ane for bacterial inoculation, monitored daily and euthanized with isofluorane overdose if they
met any early removal criteria (lethargy, hunched posture, or ruffled coat) to limit suffering.
Microbiological Methods
For routine culture, B. bronchiseptica strains were grown on Bordet Gengou agar (BGA)
(Difco) supplemented with 15% (vol/vol) defibrinated fresh sheep blood (BGA medium) at
36°C for 48 h, and replated on the same medium for 24 h. Liquid cultures were grown in
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Stainer-Scholte (SS) [17] medium at 36°C and 160 rpm. When appropriate BGA or SS was
supplemented with kanamycin (80 μg ml-1), streptomyicin (200 μg ml-1) or gentamycin
(50 μg ml-1). P. fluorescens and E. coli were grown in lysogeny broth (LB) [18] at 30°C and
37°C, respectively. When appropriate, antibiotics were added to the medium at the following
concentrations: E. coli, 10 μg ml-1 gentamycin; P. fluorescens, 30 μg ml-1 gentamycin.
Replicative plasmids were introduced to E. coli and B. bronchiseptica by electroporation
using standard techniques. Non-replicating plasmids were introduced into B. bronchiseptica by
conjugation. The yeast strain InvSc1 (Saccharomyces cerevisiae; Invitrogen), was routinely cul-
tured on YPD medium. When selecting for plasmids carrying the URA3 gene, yeast were
grown on YNB with complete supplemental mixture minus uracil.
Plasmid and Strain Construction
Strains and plasmids were constructed using standard molecular biology techniques and are
listed in S1 Table. Oligonucleotides used in this study are listed in S2 Table. Detailed descrip-
tions of strain and plasmid construction procedures can be found in the S1 Text.
Biofilm Assays
Biofilm formation assays using static cultures were performed as described previously [12]
from overnight cultures inoculated into SS liquid medium. Briefly, the culture was pipetted
into glass tubes or wells of a sterile 96-well U bottom microtiter plate (polyvinylchloride, PVC)
and incubated statically at 37°C. Nicotinic acid was added as indicated. After 24 hours, unless
otherwise indicated, planktonic bacteria were removed and the attached cells were stained with
0.1% crystal violet (CV) solution. The stain was dissolved by adding 120 μl of 33% acetic acid
solution. One hundred microliters of the dissolved stain solution was transferred to a new, flat-
bottom microplate and then quantified by measuring OD at 595 nm.
Scanning Electron Microscopy
Scanning electron microscopy pictures were obtained as described previously by Sisti et al.
[12]. Briefly, Bordetella strains were cultured statically on glass coverslips partially submerged
vertically in plastic tubes such that an air-liquid interface was established on the coverslip.
After 24 h of incubation, the coverslip was removed and washed with sterile PBS, and the bac-
teria were fixed with 2.5% glutaraldehyde in PBS. Samples were dehydrated in a graded ethanol
series (20, 50, 70, 90 and 100% for 60 min each), subjected to critical point drying using liquid
carbon dioxide (EMITECH, K850) and sputter coated with gold (SPI Supplies). The surface
topographies of the biofilm in A panels were visualized with a scanning electron microscope
(ESEM FEI QUANTA 200), and detected with SDD (EDAX Apollo 40) camera. The surface
topographies in B panels were visualized with a scanning electron microscope (Philips SEM
505), and the images were processed with the Image Soft Imaging System ADDA II.
RNA Extraction for RT-PCR Studies
RNA extraction and RT-PCR studies were performed as described previously by our group
[12]. RNA preparation from bacteria was performed using the Illustra RNAspin kit (GE, USA),
and quantification of RNA was performed using a ND-1,000 NanoDrop spectrophotometer at
260 nm. Measurements of A260/280 were used to determine the purity of the RNA. The syn-
thesis of cDNA was performed with a Reverse Transcription System kit (Promega) according
to the manufacturer’s protocol using random primers. One microgram of RNA was used for
each sample. The reaction was incubated at room temperature for 10 min, and reverse
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transcription was performed in a thermal cycler at 42°C for 15 min and 95°C for 5 min for a
total of 35 cycles. PCR was performed with Kappa Taq from Biosystems. Samples that had not
undergone the reverse transcription process were used as controls for the absence of genomic
DNA in RT-PCR experiments. Primers employed are summarized in S2 Table, including the
primers designed to amplify the intergenic region between the lapA and lapG genes. PCR anal-
ysis of internal fragment of recA gene, which is constitutively expressed, was used as control.
LapA Localization
For Western and dot blot assays of the LapA protein, we used strains with internal HA-tag
engineered into the sequence of the chromosomal lapA gene. Culture conditions, preparation
of clarified cell extracts, and analysis of samples for LapA localization were performed as
described previously without modification [19]. Detection of cell surface LapA by dot blotting
was also performed as previously described [19,20].
LapG Activity Assays
Bacterial cultures were grown overnight in LB, and clarified cell extracts were subsequently pre-
pared by sonication (4×10 s on ice) in resuspension buffer, followed by centrifugation 12 min
at 15,000 × g. As described previously [19], to assess cleavage of N-terminal domain of LapA
(N-term-LapA), cell extracts E. coli carrying the pMini-LapA plasmid were mixed 1:1 with cell
extracts from strains with and without a LapG-expressing plasmid, followed by incubation at
room temperature for 30 min. When indicated, purified P. fluorescens LapG was added (750 ng
of LapG; est. purity: 50%).
Murine Respiratory Infection Model
Female BALB/c mice (originally from National Institute of Health (USA) and maintained at
Faculty of Veterinary, National University of La Plata) 3 to 4 weeks of age were used as a model
of in vivo respiratory infection by B. bronchiseptica. Bacteria grown on BGAmedium were
resuspended and adjusted to approximately 107 CFU ml-1 in PBS. Fifty microliters of bacterial
suspension was delivered intranasally to each mouse via an air displacement pipette. At differ-
ent times post-inoculation, three to four mice from each group were euthanized and their
lungs and nose were removed aseptically. Tissues were homogenized in PBS, and appropriate
dilutions were plated onto BGA medium to determine the number of viable bacteria present in
the lungs and nose. Results presented in figures are from two independent experiments per-
formed with at least four mice per strain per time point. Counts from euthanized mice were
excluded from calculations, as described in more detail in the Results section.
Statistical Analysis
All the results were compared by analysis of variance (ANOVA) followed by the Tukey test
using Infostat software (Cordoba National University).
Results
Genes Coding for Lap-Like Proteins Are Present and Expressed in B.
bronchiseptica
We searched the B. bronchiseptica genome for genes coding for proteins with properties similar
to the LapA protein of P. fluorescens, including a type I secretion signal, a VonWillebrand fac-
tor type A domain (vWFA), an overall large size, a domain with sequence repeats, as well as
lapG- and lapD-like genes found in close proximity to the candidate LapA-like protein(s). We
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performed a BLASTP search using ~1200 C-term amino acids of P. fluorescens LapA as the
query against the available B. bronchiseptica RB50 genome. This portion of LapA includes the
vWFA domain and type I secretion signal. The search identified a protein with ~30% identity
to the query sequence; the identified protein contained a C-term domain of a putative hemoly-
sin. Inspection of the complete amino acid sequence identified a protein with LapA-like prop-
erties in B. bronchiseptica—BB_RS05895.
The BB_RS05895 ORF was recently described by Nishikawa and co-workers and named
brtA [16], thus we use that nomenclature here. The B. bronchiseptica RB50 BrtA protein is pre-
dicted to be 3345 amino acids in length, with eight repeat regions. Each repeat region is ~200
amino acids long and is composed of distinct regions designated the CADG and VCBS (Dys-
troglycan-type cadherin-like domains and Vibrio, Colwellia, Bradyrhizobium, and Shewanella
repeats superfamily respectively) domains based on conserved amino acid sequence motifs
(Fig 1, S1 Fig). Interestingly, the number of repeats in BrtA vary among B. bronchiseptica
strains. As described in S3 Table, the number of repeats varies between 2 and 15 with a median
of 3 repeats. These differences in repeat length may impact host tropism, however no correla-
tion was observed between isolate source and number of repeated regions (S3 Table). It is
important to note that many draft genomes have incomplete BrtA sequences, likely due to high
frequency of repeated sequences in this protein. Hence data regarding number of CAD-
G-IDR1-VCBS-IDR2 repeats in BrtA homologs is not available for all genomes.
While BrtA architecture is similar to the LapA protein of P. fluorescens and the RtxA protein
of Legionella pneumophila [21], the sequence of the repeat regions is distinct. Nishikawa and
colleagues showed that the BrtA protein localizes to the surface of B. bronchiseptica, and using
a brtAmutant strain, these workers also showed that BrtA is required for the adhesion to an
abiotic (polystyrene) substratum but not to rat alveolar type 2 cells [16]. Upstream of
BB_RS05895 we found BB_RS05890 and BB_RS05885, which show sequence similarity to the
Fig 1. B. bronchiseptica LapA domain organization. Diagram showing the organization of the lapD, lapG and brtA genes in B. bronchiseptica (top) as well
as the domain organization of the BrtA protein (bottom). The narrow arrows indicate the location of the primers used in the RT-PCR experiment. The thick,
black arrow indicates the specific cleavage site for LapG. The type I secretion signal (T1SS) and T1SS target domains of BrtA are also shown (orange and
cyan, respectively), as is the vonWillebrand Factor A (vWFA) domain (light green). The repeat regions are indicated by the 8 yellow barrels. Domains found
in repeated regions are also indicated: CADG domain (blue), VCBS domain (green) and IDR (interdomain region, red and yellow). The CADG and VCBS
domain names are based on core conserved amino acid.
doi:10.1371/journal.pone.0158752.g001
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P. fluorescens LapG (48% identity) and LapD (30% identity) proteins, respectively. Based on
their sequence as well as functional conservation to the P. fluorescens proteins (as described
below), we decided to name BB_RS05890 and BB_RS05885 as lapG and lapD, respectively. We
also identified a canonical predicted cleavage site for LapG (an Ala-Ala motif) in the N-termi-
nal portion of BrtA (Fig 1) [21], indicating that BrtA cell surface localization is likely controlled
by the LapG protease, a hypothesis we test further below.
The gene organization in B. bronchiseptica suggested the lapD, lapG and brtA genes are part
of an operon. Intergenic regions of 81 bp and 16 bp were found between the end of the brtA
gene and start of the lapG gene and between the lapG and lapD genes, respectively. To test
whether these genes are co-transcribed, we performed RT-PCR using primers that amplified
the intergenic region between the brtA and lapG genes (Fig 1). Results presented in Fig 2A
show that the brtA and lapG genes appear to be co-transcribed. Moreover, these genes appear
to be transcribed in both virulent and avirulent phases, as indicated by the detection of the
PCR product across a range of nicotinic acid (NA) concentrations.
We compared the amino acid sequence of the B. bronchiseptica LapD- and LapG-like pro-
teins. LapD of B. bronchiseptica has cytosolic GGDEF and EAL domains that have been shown
to be critical to the function of the LapD protein of P. fluorescens [19]. The B. bronchiseptica
LapG-like protein is 48% identical to its P. fluorescens counterpart; sequence analysis shows
that all the amino acids described by Chatterjee et al. as important for protease activity, as well
as for binding to LapD and calcium [20] are conserved between the LapG proteins of B. bronch-
iseptica and P. fluorescens.
BrtA Is Important for Biofilm Formation in a Surface-Dependent Manner
Recently BrtA was described as an avirulence factor involved in biofilm formation in B. bronch-
iseptica RB50 [16]. To confirm its role in biofilm formation, we deleted the brtA gene of B.
bronchiseptica 9.73H+. The ability to form a biofilm was evaluated by the crystal violet (CV)
biofilm assay using a 96-well polyvinylchloride (PVC) microtiter plates as described in the
Material and Methods. We determined the amount of biofilm biomass formed as a function of
NA concentration; this chemical serves as an environmental modulator of BvgAS activity [22].
As shown in Fig 2B, we observed a modest but significant reduction in the amount of biofilm
formed by a mutant lacking the BrtA protein (BbΔbrtA) at 2 mM NA. In contrast, biofilm for-
mation by the BbΔbrtA strain was substantially reduced at 2 mMNA when biofilm formation
was assessed on a hydrophilic surface (glass, Fig 2C). Taken together, our data indicate that
BrtA differentially contributes to biofilm formation on different surfaces.
B. bronchiseptica LapG Is a Protease that Cleaves the N-Terminus of
BrtA
Newell and co-workers previously described the P. fluorescensmutant PfΔlapG, a strain with a
clean deletion of the lapG gene and expressing a fully functional, HA-tagged variant of the
LapA adhesin [20]. The lack of LapG in P. fluorescens results in a strain that forms a hyper-bio-
film due to the enhanced levels of LapA on the surface of the cell [20].
We hypothesized that if the LapG-like protein of B. bronchiseptica shared function with
LapG of P. fluorescens, expression of the B. bronchiseptica LapG protein would reduce the bio-
film formed by the PfΔlapGmutant strain. The B. bronchiseptica lapG-like gene was cloned
into a broad host vector, and this construct and the vector control were introduced into the
wild-type P. fluorescens or the PfΔlapGmutant strain. Expression of the B. bronchiseptica LapG
protein in the PfΔlapG strain significantly (p< 0.01) reduced the biofilm formed compared to
Bordetella bronchiseptica Biofilm Regulation
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Fig 2. Loss of BrtA in B. bronchiseptica negatively impacts biofilm formation in vitro. (A) RT-PCR using B. bronchiseptica cDNA as template to
amplify intergenic regions between the lapA and lapG genes. The recA amplicon was used as a positive control for the constitutively expressed recA
gene. cDNA obtained from wild type B. bronchiseptica grown in different NA concentrations was employed in these assays. Note: the RT-PCR assays
used are not quantitative, but are useful for detecting the presence/absence of a transcript. (B) Biofilm development by the BbWT and BbΔbrtA strains
cultured in SS medium either alone or supplemented with NA at the indicated concentration. Biofilm formation was assessed by PVCmicrotiter plate
assays as described in the Materials and Methods. *, indicates a significant difference between the wild type and mutant with same concentration of NA,
p<0.01. After incubation in static conditions, the medium was removed, the bacteria were stained with CV, and the extent of biofilm formation quantified.
(C) Biofilm formation by the BbWT and BbΔbrtA strains assessed in SS supplemented with NA 2.0 mM in glass tubes.
doi:10.1371/journal.pone.0158752.g002
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the same mutant carrying pEmpty control vector (Fig 3A). Expression of the P. fluorescens
LapG protein in the PfΔlapGmutant served as a positive control for this assay.
To confirm that the reduction in biofilm formation caused by the expression of the B.
bronchiseptica LapG protein in the PfΔlapGmutant was due to a reduction in LapA on the cell
Fig 3. B. bronchiseptica LapG and LapD complement their respective P. fluorescens mutations. (A) Biofilm formation by the P. fluorescens ΔlapG
mutant (PfΔlapG) carrying plasmids expressing the B. bronchiseptica or P. fluorescens lapG genes was determined by the CV biofilm assay. (B) Cell surface
levels of LapA as measured by dot blot. Shown is a representative dot blot assay (top) and quantification of the pixel density (n = 6 ± SD; bottom) to assess
the level of cell surface LapA of the P. fluorescens strains expressing LapG or LapD, as well as indicated control strains. *, ** or *** indicate significant
differences between strains, p<0.05, p<0.01 and p<0.005 respectively. (C) Biofilm formation by the P. fluorescens ΔlapDmutant (PfΔlapD) carrying plasmids
expressing the B. bronchiseptica or P. fluorescens lapD genes was determined by the CV biofilm assay. *, ** or *** indicate significant differences between
strains, p<0.05, p<0.01 and p<0.005 respectively.
doi:10.1371/journal.pone.0158752.g003
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surface, we performed the reported dot blot assay [19] to quantify cell-surface localized LapA
protein in P. fluorescens. LapA was indeed reduced on the bacterial cell surface when B. bronch-
iseptica LapG was expressed in the PfΔlapGmutant (Fig 3B, first 4 bars), suggesting that LapG
of B. bronchiseptica is indeed a protease that can target P. fluorescens LapA as a substrate.
To confirm that B. bronchiseptica LapG is a protease that cleaves BrtA we performed bio-
chemical assays using two different approaches. In the experiment shown in Fig 4A, the indi-
cated P. fluorescens strain was transformed with a vector control (pMQ72), a plasmid carrying
the LapG protease from P. fluorescens (LapGPf) as a positive control, or B. bronchiseptica
(LapGBb). In these assays, we assess LapG activity by measuring the amount of LapA protein of
P. fluorescens released into the supernatant; detecting supernatant LapA requires a functional
LapG protease. The source of LapA in these studies is the chromosomally-encoded LapA modi-
fied with an HA-tag to facilitate its detection. As expected, in the wild type P. fluorescens strain
(PfWT, Fig 4A, lane 2), LapA protein can be detected in the supernatant but no LapA is
detected in the P. fluorescens strain lacking LapG (PfΔlapG, Fig 4A, lane 3). As an additional
Fig 4. B. bronchiseptica LapG cleaves P. fluorescens LapA andB. bronchiseptica BrtA. (A) Cleavage of LapA-HA
from the surface of P. fluorescens cells with B. bronchiseptica LapG.Western blot with anti-HA antibodies were used to
detect LapA-HA of P. fluorescens released into the supernatant fraction for each indicated strain. (B) Cleavage of N-
terminal fragment of BrtA by B. bronchiseptica LapG in vitro. Samples correspond to reaction mixture of E. coli lysate
expressing indicated protein or empty vector with E. coli lysate expressing the N-terminus of BrtA (N-term BrtA) incubated at
room temperature for 1h. Western blot with anti-HA antibodies was used to detect N-term BrtA.
doi:10.1371/journal.pone.0158752.g004
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control, we see abundant LapA in the supernatant in a lapDmutant strain (PfΔlapD, Fig 4A,
lane 4); a lapDmutation results in high, unregulated LapG activity, and thus serves as an addi-
tional positive control for LapA release into the supernatant.
Our data indicate that B. bronchiseptica LapG can indeed substitute for the LapG protein of
P. fluorescens as indicated by its ability to release LapA into the supernatant (Fig 4A, lane 7),
albeit to a lesser extent than the P. fluorescens LapG protein (Fig 4A, lane 5). In the P. fluores-
cens strain lacking LapG (PfΔlapG) carrying the pMQ72 vector (lane 6), as expected, no LapA
was detected in the supernatant. These data are consistent with the hypothesis that B. bronchi-
septica LapG is a protease that can target cell-surface adhesins like LapA.
To extend the finding in Fig 4A to an in vitro system, an E. coli strain expressing B. bronchi-
septica LapG was grown, concentrated and sonicated to generate a crude cell-free extract, as
described in the Materials and Methods. Crude cell free extracts of E. coli containing the HA-
tagged, N-term fragment of B. bronchiseptica BrtA (N-term BrtA, amino acids 1–330) were
also generated. The crude extract containing B. bronchiseptica LapG was mixed in a 1:1 ratio
with the extract containing the N-terminal fragment of B. bronchiseptica BrtA, incubated at
room temperature for 1 hr, then analyzed by Western blotting using an anti-HA-tag antibody
to detect processing of BrtA. As a positive control, LapG from P. fluorescens was shown to pro-
cess N-term BrtA, and B. bronchiseptica LapG was also able to cleave the N-terminal fragment
of B. bronchiseptica BrtA (Fig 4B). Interestingly, B. bronchiseptica LapG only cleaved BrtA in
presence of 10 mM calcium. This finding is consistent with previous work showing that the
LapG protein of P. fluorescens is a calcium-dependent enzyme [23]. Interestingly, Nishikawa
and colleagues observed that treatment of B. bronchiseptica with EGTA, a calcium chelator,
reduced biofilm formation; this reduction in biofilm formation may be due to the need for cal-
cium to promote proper folding of some secreted proteins [24,25].
B. bronchiseptica LapD Appears Partially Functional in P. fluorescens
The B. bronchiseptica lapD-like gene was cloned in a broad host vector to evaluate its ability to
complement the phenotype of a lapDmutant of P. fluorescens (PfΔlapD). The PfΔlapD strain
shows reduced biofilm formation and low LapA levels on the bacterial surface compared with
the wild type [19]. When the B. bronchiseptica lapD gene was expressed in the PfΔlapD strain,
partial complementation was observed in CV biofilm assay (Fig 3C). The level of cell surface
LapA in the strain carrying the B. bronchiseptica LapD was increased to an extent similar to
that observed when the P. fluorescens lapD gene was introduced into this strain (Fig 3B). We
do not understand why the increase in cell surface LapA to wild-type levels in the strain carry-
ing B. bronchiseptica LapD does not also result in an increase in biofilm formation to levels
equivalent to the wild-type strain.
The Deletion or Over-Expression of LapG Alters Biofilm Formation by B.
bronchiseptica
Previous studies of P. fluorescens showed that unregulated LapG expression results in increased
cleavage of LapA and the release of this adhesin into the supernatant, results in reduced biofilm
formation. In contrast, deleting the lapG gene of P. fluorescens results in enhanced levels of
LapA on the cell surface and increased biofilm formation [20]. Thus, we assessed the effect of
expressing LapG from a plasmid and deleting the gene from the chromosome on biofilm for-
mation by B. bronchiseptica as a function of NA, an in vitro regulator of biofilm formation.
We hypothesized that expression of B. bronchiseptica LapG under a constitutive promoter
would decrease biofilm formation in B. bronchiseptica. As expected, LapG overexpression
resulted in significantly (p<0.001) reduced biofilm formation (Fig 5A) but only at low
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concentrations of NA added 0, 0.5 and 1 mM. At the highest concentration of NA tested (4.0
mM), where the extent of biofilm formation was the lowest, expression of the B. bronchiseptica
LapG did not further reduce biofilm formation.
Based on the work in P. fluorescens, we would expect a B. bronchiseptica strain with a dele-
tion of the lapG gene to develop very robust biofilms compared to the wild type. As expected,
the B. bronchiseptica strain lacking the lapG gene (BbΔlapG) showed more biofilm formation
compared to wild type at the higher concentrations of NA tested, and this defect could be com-
plemented in trans by a wild-type copy of LapGBb (Fig 5B). This phenotype was observed on
either a PVC (Fig 5B) or glass surface (not shown).
The observations in Fig 5 using the microtiter plate assay were confirmed by SEM analysis
of biofilm structures formed in the air-liquid interface using glass as an abiotic surface. Fig 6
shows representative SEM images of the biofilms formed by strains over-expressing LapG com-
pared to a vector control (Fig 6A) and in a strain lacking the lapG gene compared to the wild
type (Fig 6B). As a control, deletion of the brtA gene reduced (but did not eliminate) the bio-
film formed under these conditions (Fig 6B). Similar results were observed when fluorescence
microscopy was employed (S2 Fig).
LapGMay Contribute to Infection In Vivo
Biofilm formation on epithelial cells in the nose is thought to be a key early step in Bordetella
infection [9]. Given the role of BrtA and LapG for in vitro biofilm formation, we hypothesized
that these proteins might also play a role during colonization in vivo. We intranasally inocu-
lated suspensions of the wild type or mutant B. bronchiseptica strains into BALB/c mice, and
the infection progress was evaluated for 21 days in the nose and lungs (Fig 7).
Mice were infected with wild type B. bronchiseptica as previously described [4]. Wild type
bacteria persisted in lung and nose mice after 21 days post infection. A typical B. bronchiseptica
infection was observed; lung burden increased during the first 7 days and this microbe was
gradually reduced across the remainder of the experiment. Our analysis indicates that BrtA
Fig 5. LapG regulates biofilm formation by B. bronchiseptica. (A) Biofilm formation in different NA concentrations by the wild type carrying a vector
control (Bb-pEmpty) or a plasmid over-expressing B. bronchiseptica LapG (Bb-lapG). *, indicates a significant difference versus the Bb-pEmpty in same NA
concentration, p<0.001. (B) Biofilm formation by the wild-type strain carrying a vector control (Bb-pEmpty), a strain with a deletion of the lapG gene carrying a
vector control (BbΔlapG-pEmpty), and the BbΔlapGmutant complemented with a wild-type copy of the B. bronchiseptica lapG gene (BbΔlapG-pLapG).
Biofilm formation was assessed using the microtiter plate assays as described in the Materials and Methods. *, indicates a significant difference in the
indicated comparisons, p<0.001.
doi:10.1371/journal.pone.0158752.g005
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does not contribute to bacterial burden at any stage during infection in either body site evalu-
ated (Fig 7). For the strain lacking the lapG gene (BbΔlapG), there was a small but statistically
significant increase in bacterial burden at 14 days for those mice that survived until the end of
the experiment, but no significant difference was detected at any other time point (Fig 7).
Interestingly, across all experiments, 25% of BbΔlapG infected mice presented symptoms of
illness (indicated by ruffled fur, labored breathing, and diminished responsiveness) and were
euthanized to avoid suffering (S3 Fig). Lungs of these euthanized mice carrying the BbΔlapG
strain had on average 3 x 108 CFU ml-1, a significant increase of 1–2 log over the wild type (7 x
106 CFU ml-1) and the mice carrying the BbΔlapGmutant that survived until the end of the
experiment. These data indicated the possibility that loss of LapG function by B. bronchiseptica
could contribute to enhanced virulence, at least in some circumstances.
Fig 6. SEM images ofB. bronchiseptica biofilms. (A) The strains Bb-pEmpty (left column of panels) or Bb-pLapG (right column of panels) were grown on
vertically submerged coverslips in SSmedium alone or supplemented with indicated NA concentrations. After 24 h of growth, biofilms formed at the air–liquid
interface were visualized by SEM. (B) Indicated strains were grown on vertically submerged coverslips in SS medium alone (left column of panels) or SS
supplemented with 2.0 mMNA (right column of panels).
doi:10.1371/journal.pone.0158752.g006
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Discussion
In this work we analyze the BrtA protein of B. bronchiseptica, a predicted adhesin based on its
similarity in domain structure to the LapA adhesin of P. fluorescens. We confirm the recent
finding of Nishikawa and colleagues [16] that BrtA participates in biofilm formation by B.
bronchiseptica, and build on this recent study by identifying and characterizing homologs of
the LapD and LapG proteins of P. fluorescens. In P. fluorescens, LapD and LapG participate in
the regulation of cell surface localization of the LapA protein; we show that the B. bronchisep-
tica LapD and LapG proteins likely play a similar role for BrtA. We also demonstrate that loss
of BrtA results in a mild biofilm defect on plastic, and a much more severe defect in biofilm for-
mation on glass, a hydrophilic substrate. BrtA, while having limited sequence similarity to the
LapA protein of P. fluorescens shares a number of conserved features, including T1SS and
vWFA domains, and the conserved Ala-Ala motif near its N-terminus that serves as the site of
proteolysis in LapA for the LapG protein of P. fluorescens.
In P. fluorescens, the localization of the LapA protein to the surface of the cell is postran-
scriptionally regulated by LapG. LapG is a periplasmic protease that targets the N-terminus
of LapA and cleaves this adhesin at a conserved Ala-Ala motif, resulting in release of LapA
into the supernatant. Loss of LapA results in a reduction in biofilm formation by P. fluores-
cens. The LapD protein of P. fluorescens, in response to c-di-GMP levels in the cytoplasm,
regulates LapG’s ability to target LapA by sequestering LapG via a protein-protein interac-
tion mechanism [20,26]. The studies presented here indicate that the LapD and LapG pro-
teins of B. bronchiseptica likely play a similar role in the context of BrtA. Our in vivo and in
vitro studies, including complementation assays, support the conclusion that LapG is a
Fig 7. B. bronchiseptica infection in a mousemodel. Comparison of B. bronchiseptica bacterial burden in the mouse nose (A) and lungs (B) were
determined as described in the Materials and Methods after the indicated days post-infection. Bacteria were intranasally inoculated into external nares with
an air displacement pipette (5 x 105 CFU in 50 μl). Green dots correspond to CFU from euthanized mice infected with BbΔlapG. * indicates a significant
difference compared to the CFU determined in mice infected with wild type strain, p<0.01.
doi:10.1371/journal.pone.0158752.g007
Bordetella bronchiseptica Biofilm Regulation
PLOS ONE | DOI:10.1371/journal.pone.0158752 July 5, 2016 13 / 16
protease that targets the N-terminal domain of BrtA for cleavage, thereby negatively impact-
ing biofilm formation. Similarly, our studies implicate LapD in the control of LapG in B.
bronchiseptica.
An interesting observation from our SEM and fluorescence microscopy studies was that in a
mutant lacking BrtA, biofilm formation was reduced but not eliminated. This observation sug-
gested that there may be at least one other adhesin contributing to biofilm formation on abiotic
surfaces. Previous reports implicated FHA and the adenylate cyclase enzyme as involved in bio-
film formation by Bordetella [7,11], further work should be directed at assessing the role of
these proteins (or others) in the context of a strain lacking BrtA. Interestingly, BrtA appeared
to play no detectable role in disease progression in a mouse model of infection; there was no
change in bacterial burden in the nose or lungs of mice for up to 21 days post-infection in the
brtAmutant strain compared to the wild type. This finding is consistent with the work of
Nishikawa and colleagues who showed that a brtAmutant of B. bronchiseptica showed no
defect in a model of rat nasal septum and tracheal colonization. Given that BrtA plays a role in
biofilm formation on abiotic surfaces, we propose that a major role for this adhesion might be
in environmental persistence as the microbe transits between hosts.
A strain of B. bronchiseptica lacking LapG function, which presumably has increased cell-
surface BrtA based on our in vitro studies, when infecting mice, yielded two distinct pheno-
types. In 75% of the animals, infection was maintained for 21 days with a bacterial burden simi-
lar to the wild type, with the exception of a small but significant increase in bacterial numbers
in lungs at day 14 post-infection. However, 25% of the mice infected with the B. bronchiseptica
lapGmutant showed increased disease symptoms that resulted in the need to euthanize these
animals typically between days 4–9. These data may indicate that BrtA, when present in larger
levels on the cell surface can enhance virulence, at least in some animals. However, given the
lack of impact upon loss of BrtA function in this infection model, it is also possible that LapG
may have (at least) one other target in B. bronchiseptica. Distinguishing between these possibil-
ities should be explored in future studies.
Overall, we have established that the LapD/LapG system of this pathogen likely functions in
an analogous manner to the well-described system in P. fluorescens. In B. bronchiseptica, the
target of the LapD/LapG system appears to be BrtA, a LapA-like protein that has a clear role in
biofilm formation on abiotic surfaces. The role of the LapD/LapG system in a mouse model of
infection is less clear—additional investigation will be required to dissect the role (if any) of
BrtA and the LapD/LapG system in host-pathogen interactions.
Supporting Information
S1 Fig. Weblogo diagram of the repeated regions (CADG-IDR1-VCBS-IDR2) in BrtA. A
consensus sequence among the eight repeat regions in BrtA is shown.
(TIF)
S2 Fig. Fluorescent microscopy of B. bronchiseptica biofilm on glass surface. Bordetella
strains were cultured on glass coverslips as described for the SEM studies. After 12 hr of incu-
bation the coverslips were washed with sterile PBS, and the bacteria were fixed with 4% formal-
dehyde in PBS. The samples were observed in a Nikon Ti-U Fluorescence Microscope, and the
images were obtained with a Nikon Digital Sight DS Ri1 camera using the Nis-Elements soft-
ware. White bars indicate 100 μm.
(TIF)
S3 Fig. Survival of mice infected with wild type or lapGmutant B. bronchiseptica. Kaplan
Meier survival curve is represented for mice infected with BbWT (blue line) or BbΔlapG (red
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line). The difference between the survival curves was analyzed by the log-rank test (z = 1.98;
p = 0.047 with 95% confidence).
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